BerGenBio presents new Phase II clinical data that bemcentinib in combination with low dose chemotherapy improves efficacy and duration of survival in elderly AML patients at ASCO 2019

· Phase II trial evaluating bemcentinib in combination with low-intensity chemotherapy in elderly AML patients unfit for intensive therapy shows promising efficacy · 6 out of 13 (46%) patients receiving LDAC combination achieved an Overall Response Rate (ORR) of 46% · 3 out of 12 evaluable patients receiving decitabine combination achieved an ORR of 25% · ORR significantly higher than previously observed/historical benchmarks in single-agent cytarabineChicago, USA, 03 June 2019 – BerGenBio ASA (OSE:BGBIO) today presents data showing significant efficacy in Phase II clinical trials (